Altamira Therapeutics Ltd.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Thomas Meyer
- Full Time Employees
- 10
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Clarendon House Hamilton Bermuda HM 11
- IPO Date
- Aug 6, 2014
- CIK
- 0001601936
- Website
- altamiratherapeutics.com
- Similar Companies
- Business
- Altamira Therapeutics Ltd. is a clinical-stage biopharmaceutical company developing peptide-based nanoparticle technologies for RNA delivery to extrahepatic tissues and nasal spray therapies for inner ear disorders. The company supplies its xPhore platform, including OligoPhore, SemaPhore, and CycloPhore technologies, for efficient delivery of siRNA, antisense oligonucleotides, mRNA, and other RNA modalities to non-liver targets via systemic or local administration; flagship programs include AM-401, a siRNA therapy using OligoPhore for KRAS-driven cancers to inhibit tumor cell proliferation, and AM-411, a siRNA therapy using SemaPhore targeting the NF-kB pathway for rheumatoid arthritis, both in preclinical development beyond in vivo proof-of-concept. It also offers Bentrio, a drug-free nasal spray safeguarding against airborne viruses and allergens; AM-125, an intranasal betahistine formulation in post-Phase II trials for acute vertigo; and legacy assets such as AM-111, a cell-penetrating peptide in Phase III for acute inner ear hearing loss with orphan drug designation, and AM-102, a small molecule in preclinical stage for tinnitus. Founded in 2003 as Auris Medical Holding Ltd. and renamed Altamira Therapeutics Ltd. in July 2021, the company is headquartered in Hamilton, Bermuda, with main operations in Basel, Switzerland, and activities spanning Switzerland, Australia, the United States, and Europe. In recent developments, Altamira expanded its RNA delivery partnerships, initiating collaborations in 2024 with Univercells Group for SemaPhore in mRNA vaccines and securing two additional undisclosed partners in 2025 for SemaPhore with radiopharmaceuticals in cancer treatment and CycloPhore for circular RNA, while pursuing further licensing deals and expecting at least one more agreement in 2025. The company raised funding in 2024 to advance OligoPhore and SemaPhore platforms and support programs like AM-401 and AM-411, alongside divesting or out-licensing legacy assets in allergology, viral infections, and inner ear therapeutics including AM-111 and AM-102. Its R&D team relocated to Switzerland Innovation Park Basel Area facilities to enhance RNA platform capabilities, bolster IP, and foster collaborations in oncology and inflammatory diseases.
Altamira Therapeutics Announces Transition from NASDAQ to OTC Markets
Here's Why Auris (CYTO) Is a Great 'Buy the Bottom' Stock Now
Altamira Therapeutics Provides Update on Nasdaq Listing
Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray
Altamira Therapeutics Ltd. (CYTO) Q2 2024 Earnings Call Transcript
Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results
Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024
Altamira Therapeutics Announces Closing of up to $12.0 Million Public Offering
Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering
Altamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11
REPEAT -- Diamond Equity Research Releases Update Note on Altamira Therapeutics Ltd. (NASDAQ: CYTO)
Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and Denmark
Altamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited Substances
Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination with Zbtb46 mRNA Delivered with SemaPhore Nanoparticles in Animal Tumor Models
Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore Nanoparticles
Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management
Altamira Therapeutics Provides Business Update
Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy Journal
Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation
Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal